Haemonetics (NYSE:HAE) Shares Down 5.6% – Time to Sell?

Haemonetics Corporation (NYSE:HAE) shares were down 5.6% during mid-day trading on Friday . The stock traded as low as $60.32 and last traded at $61.4050. Approximately 451,712 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 861,341 shares. The stock had previously closed at $65.02.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 results beat consensus: HAE reported $1.31 EPS vs. $1.27 expected and revenue of $338.97M vs. ~$331.9M, with margins improving—evidence of profitable execution. Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company raised FY‑2026 outlook and signaled strong organic growth (management highlighted plasma and blood‑management strength and an 8%–10% organic growth outlook), which supports longer‑term revenue momentum. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: Analyst support remains: BTIG reaffirmed a “buy” and a $88 price target, indicating continued analyst conviction above current levels. Benzinga coverage of BTIG rating
• Neutral Sentiment: Investor materials and transparency: the company posted its press release, slide deck and earnings‑call transcript for review—useful for digging into segment trends and guidance detail. PR Newswire: Q3 financial results available
• Neutral Sentiment: Zacks highlights HAE as a top‑ranked growth stock by style scores—an informational signal for growth‑oriented investors but not an immediate price catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Revenue weakness and mixed investor reaction: revenue fell ~2.7% YoY despite the beat, and the market reacted negatively (shares slipped after the report)—suggesting investors wanted stronger top‑line improvement or more aggressive guidance. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. Mizuho lowered their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday. BTIG Research reiterated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.80.

Haemonetics Stock Performance

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The stock has a market cap of $2.78 billion, a P/E ratio of 17.37, a P/E/G ratio of 1.37 and a beta of 0.28. The business’s 50-day moving average price is $77.28 and its 200-day moving average price is $65.27.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the company posted $1.19 earnings per share. Haemonetics’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of the company. True Wealth Design LLC boosted its holdings in Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 335 shares during the period. Leonteq Securities AG purchased a new position in shares of Haemonetics in the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. Bayforest Capital Ltd bought a new position in shares of Haemonetics in the fourth quarter worth about $40,000. Finally, Allworth Financial LP boosted its stake in shares of Haemonetics by 390.8% in the fourth quarter. Allworth Financial LP now owns 746 shares of the medical instruments supplier’s stock worth $60,000 after acquiring an additional 594 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.